Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

Neuron

Volumn 43, Issue 3, 2004, Pages 321-332

  Oddo, Salvatore ^a,b   Billings, Lauren ^a,b   Kesslak, J Patrick ^b   Cribbs, David H ^b   LaFerla, Frank M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; EPOXOMICIN; GAMMA SECRETASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1560; MONOCLONAL ANTIBODY 4G8; PROTEASOME; PROTEASOME INHIBITOR; TAU PROTEIN; UNCLASSIFIED DRUG; ALZHEIMER DISEASE VACCINE; ANTIBODY; CYSTEINE PROTEINASE; MULTIENZYME COMPLEX;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; IMMUNIZATION; IMMUNOTHERAPY; MALE; MODEL; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; COMPARATIVE STUDY; DRUG ANTAGONISM; EXTRACELLULAR FLUID; GENETICS; IMMUNOLOGY; INTRACELLULAR FLUID; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; CYSTEINE ENDOPEPTIDASES; EXTRACELLULAR FLUID; FEMALE; HIPPOCAMPUS; INJECTIONS, INTRAVENTRICULAR; INTRACELLULAR FLUID; MALE; MICE; MICE, TRANSGENIC; MULTIENZYME COMPLEXES; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; TAU PROTEINS;

EID: 4043167747     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2004.07.003     Document Type: Article

References (33)

1. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:2000;916-919
2. Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature. 415:2002;462
3. David D.C., Layfield R., Serpell L., Narain Y., Goedert M., Spillantini M.G. Proteasomal degradation of tau protein. J. Neurochem. 83:2002;176-185
4. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5:2002;452-457
5. Dovey H.F., John V., Anderson J.P., Chen L.Z., de Saint Andrieu P., Fang L.Y., Freedman S.B., Folmer B., Goldbach E., Holsztynska E.J., et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 76:2001;173-181
6. Goldbaum O., Oppermann M., Handschuh M., Dabir D., Zhang B., Forman M.S., Trojanowski J.Q., Lee V.M., Richter-Landsberg C. Proteasome inhibition stabilizes tau inclusions in oligodendroglial cells that occur after treatment with okadaic acid. J. Neurosci. 23:2003;8872-8880
7. Goldberg A.L. Protein degradation and protection against misfolded or damaged proteins. Nature. 426:2003;895-899
8. Gotz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 293:2001;1491-1495
9. Gregori L., Fuchs C., Figueiredo-Pereira M.E., Van Nostrand W.E., Goldgaber D. Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J. Biol. Chem. 270:1995;19702-19708
10. Gregori L., Hainfeld J.F., Simon M.N., Goldgaber D. Binding of amyloid beta protein to the 20 S proteasome. J. Biol. Chem. 272:1997;58-62
11. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease. progress and problems on the road to therapeutics Science. 297:2002;353-356
12. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 38:2003;547-554
13. Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 393:1998;702-705
14. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;979-982
15. Keck S., Nitsch R., Grune T., Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J. Neurochem. 85:2003;115-122
16. Keller J.N., Hanni K.B., Markesbery W.R. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75:2000;436-439
17. Lanz T.A., Himes C.S., Pallante G., Adams L., Yamazaki S., Amore B., Merchant K.M. The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L- alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J. Pharmacol. Exp. Ther. 305:2003;864-871
18. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 293:2001;1487-1491
19. Lindsten K., Menendez-Benito V., Masucci M.G., Dantuma N.P. A transgenic mouse model of the ubiquitin/proteasome system. Nat. Biotechnol. 21:2003;897-902
20. Lopez Salon M., Morelli L., Castano E.M., Soto E.F., Pasquini J.M. Defective ubiquitination of cerebral proteins in Alzheimer's disease. J. Neurosci. Res. 62:2000;302-310
21. Mendell J.R., Sahenk Z., Gales T., Paul L. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch. Neurol. 48:1991;1229-1234
22. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985
23. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide. a case report Nat. Med. 9:2003;448-452
24. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging. 24:2003;1063-1070. a
25. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles. intracellular Aβ and synaptic dysfunction Neuron. 39:2003;409-421. b
26. Rapoport M., Dawson H.N., Binder L.I., Vitek M.P., Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA. 99:2002;6364-6369
27. Rissman R.A., Poon W.W., Blurton-Jones M., Oddo S., Torp R., LaFerla F.M., Rohn T.T., Cotman C.W. Caspase-cleavage of tau is an early event in neurofibrillary pathology in Alzheimer's disease. J. Clin. Invest. 114:2004;121-130
28. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177
29. Sigurdsson E.M., Scholtzova H., Mehta P.D., Frangione B., Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 159:2001;439-447
30. Tseng B.T., Kitazawa M., LaFerla F.M. Amyloid [beta]-peptide. the inside story Curr. Alzheimer's Res. in press:2004
31. Weaver C.L., Espinoza M., Kress Y., Davies P. Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol. Aging. 21:2000;719-727
32. Wilcock D.M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K.E., Gordon M.N., Morgan D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 23:2003;3745-3751
33. Wilcock D.M., Munireddy S.K., Rosenthal A., Ugen K.E., Gordon M.N., Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol. Dis. 15:2004;11-20